Turtle Cameron, Spyre Therapeutics’ CEO, sold 15,000 shares across four transactions priced from $86.36 to $89.07 per share. The post-transaction ownership figure was 552,540 shares, giving investors the reported scale of Cameron’s remaining position after the sale.

Key Highlights

  • The transactions took place on 1 September 2026.
  • Each of the four transactions carried transaction code S.
  • Turtle Cameron was identified as Spyre Therapeutics’ chief executive officer.

Spyre Therapeutics, Inc. (NASDAQ: SYRE) CEO Turtle Cameron sold 15,000 shares at prices ranging from $86.36 to $89.07 per share. Cameron’s reported ownership after the transactions stood at 552,540 shares.

Four Transactions Completed on September 1

Cameron completed the sales through four separate transactions involving Spyre Therapeutics shares. Each transaction used transaction code S. The transactions occurred on 1 September 2026. Cameron is identified as Spyre Therapeutics’ chief executive officer. The reported prices extended from $86.36 to $89.07 per share across the transactions. The total Volume sold was 15,000 shares.

Post-Transaction Ownership Listed at 552,540 Shares

That post-transaction figure is stated separately from the 15,000 shares sold. The ownership figure records Cameron’s reported position following the four sales.